C-reactive Protein and 5-year Survival in Type 2 Diabetes: the Casale Monferrato Study
Overview
Authors
Affiliations
Objective: To determine to what extent plasma C-reactive protein (CRP) values influence 5-year all-cause and cardiovascular mortality in type 2 diabetic individuals, independently of albumin excretion rate (AER) and other cardiovascular risk factors, and its incremental usefulness for predicting individual risk of mortality.
Research Design And Methods: Measurements of CRP were performed in 2,381 of 3,249 (73.3%) subjects as part of the population-based Casale Monferrato Study. Its association with 5-year all-cause and cardiovascular mortality was assessed with multivariate Cox proportional hazards modeling. The C statistic and measures of calibration and global fit were also assessed.
Results: Results are based on 496 deaths in 11.717 person-years of observations (median follow-up 5.4 years). With respect to subjects with CRP < or =3 mg/l, those with higher values had an adjusted hazard ratio (HR) of 1.51 (95% CI 1.18-1.92) for all-cause mortality and 1.44 (0.99-2.08) for cardiovascular mortality. In normoalbuminuric subjects, respective HRs of CRP were 1.56 (1.13-2.15) and 1.65 (1.00-2.74), AER being neither a modifier nor a confounder of CRP association. In analysis limited to diabetic subjects without cardiovascular disease (CVD), adjusted HRs were 1.67 (1.24-2.24) for all-cause mortality and 1.36 (0.83-2.24) for cardiovascular mortality. The improvement in individual risk assessment was marginal when measured with various statistical measures of model discrimination, calibration, and global fit.
Conclusions: CRP measurement is independently associated with short-term mortality risk in type 2 diabetic individuals, even in normoalbuminuric subjects and in those without a previous diagnosis of CVD. Its clinical usefulness in individual assessment of 5-year risk of mortality, however, is limited.
Chen Y, Ju H, Xie K, Zhao X Front Immunol. 2024; 15:1410871.
PMID: 39011047 PMC: 11246876. DOI: 10.3389/fimmu.2024.1410871.
Khonglah D, Pal A, Mallik N, Ray D, Ghosal M, Acharya R Indian J Psychiatry. 2023; 65(4):472-476.
PMID: 37325099 PMC: 10263090. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_380_22.
Inflammation, dysregulated iron metabolism, and cardiovascular disease.
Rosenblum S Front Aging. 2023; 4:1124178.
PMID: 36816471 PMC: 9935942. DOI: 10.3389/fragi.2023.1124178.
Eljalby M, Huang X, Becher T, Wibmer A, Jiang C, Vaughan R Am J Physiol Endocrinol Metab. 2022; 324(2):E144-E153.
PMID: 36576355 PMC: 9902220. DOI: 10.1152/ajpendo.00187.2022.
Huang N, Tang C, Li S, Ma W, Zhai X, Liu K Front Cardiovasc Med. 2022; 9:976817.
PMID: 36158788 PMC: 9500166. DOI: 10.3389/fcvm.2022.976817.